» Articles » PMID: 38566907

Revealing Stromal and Lymphoid Sources of -expression During Inflammation Using a Novel Reporter Mouse

Overview
Journal Discov Immunol
Date 2024 Apr 3
PMID 38566907
Authors
Affiliations
Soon will be listed here.
Abstract

One of the earliest signs of dysregulation of the homeostatic process of fibrosis, associated with pathology in chronic conditions such as rheumatoid arthritis, is the overexpression of collagen type III (COL-3). Critically, there is still relatively little known regarding the identity of the cell types expressing the gene encoding COL-3 (). Identifying and characterizing -expressing cells during the development of fibrosis could reveal new targets for the diagnosis and treatment of fibrosis-related pathologies. As such, a reporter mouse expressing concomitantly and mKate-2, a fluorescent protein, was generated. Using models of footpad inflammation, we demonstrated its effectiveness as a tool to measure the expression of COL-3 during the repair process and provided an initial characterization of some of the stromal and immune cells responsible for expression.

References
1.
Nazari B, Rice L, Stifano G, Barron A, Wang Y, Korndorf T . Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90. Am J Pathol. 2016; 186(10):2650-64. PMC: 5222985. DOI: 10.1016/j.ajpath.2016.06.020. View

2.
Montesi S, Desogere P, Fuchs B, Caravan P . Molecular imaging of fibrosis: recent advances and future directions. J Clin Invest. 2019; 129(1):24-33. PMC: 6307954. DOI: 10.1172/JCI122132. View

3.
Kuivaniemi H, Tromp G . Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases. Gene. 2019; 707:151-171. PMC: 6579750. DOI: 10.1016/j.gene.2019.05.003. View

4.
Wynn T . Cellular and molecular mechanisms of fibrosis. J Pathol. 2007; 214(2):199-210. PMC: 2693329. DOI: 10.1002/path.2277. View

5.
Poo J, Torre A, Aguilar-Ramirez J, Cruz M, Mejia-Cuan L, Cerda E . Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study. Hepatol Int. 2020; 14(5):817-827. PMC: 7561536. DOI: 10.1007/s12072-020-10069-3. View